Andreozzi, F.; Dragani, M.; Quivoron, C.; Le Bras, F.; Assi, T.; Danu, A.; Belhadj, K.; Lazarovici, J.; Cotteret, S.; Bernard, O.A.;
et al. Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study. Cancers 2023, 15, 1508.
https://doi.org/10.3390/cancers15051508
AMA Style
Andreozzi F, Dragani M, Quivoron C, Le Bras F, Assi T, Danu A, Belhadj K, Lazarovici J, Cotteret S, Bernard OA,
et al. Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study. Cancers. 2023; 15(5):1508.
https://doi.org/10.3390/cancers15051508
Chicago/Turabian Style
Andreozzi, Fabio, Matteo Dragani, Cyril Quivoron, Fabien Le Bras, Tarek Assi, Alina Danu, Karim Belhadj, Julien Lazarovici, Sophie Cotteret, Olivier A. Bernard,
and et al. 2023. "Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study" Cancers 15, no. 5: 1508.
https://doi.org/10.3390/cancers15051508
APA Style
Andreozzi, F., Dragani, M., Quivoron, C., Le Bras, F., Assi, T., Danu, A., Belhadj, K., Lazarovici, J., Cotteret, S., Bernard, O. A., Ribrag, V., & Michot, J.-M.
(2023). Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study. Cancers, 15(5), 1508.
https://doi.org/10.3390/cancers15051508
